A. W. Burrell (Managing Director, Travenol) wrote a letter to Dr Walford advising her that "well before" the FDA's 24 March recommendation, Hyland had taken steps to introduce screening procedures designed to eliminate high-risk donors.
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Regulation of Commercial Factor Concentrates
Key Person(s)
Dr Diana Walford